Skip to main content

Agilent and ExonHit Partner to Develop Microarray for Splice Variants

NEW YORK, Nov. 15 (GenomeWeb News) - Agilent Technologies will combine its microarray platform with ExonHit's alternative RNA splicing in an attempt to develop an array technology that can monitor the expression of splice variants, the companies said today.


The companies presented results from an experimental splicing array of G-protein coupled receptors, which was designed by ExonHit and produced by Agilent, at the Splicing 2004 meeting, held in September in Bethesda, Md.


That array was bale to detect multiple isoforms of several genes, and "showed good reproducibility and specificity," the companies said in a statement today. Agilent and ExonHit "are expected to work with early test sites to generate additional experimental results," the firms said.

Financial terms of the agreement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.